Molecular and biotechnological advances in milk proteins in relation to human health

Current Protein and Peptide Science

Volumn 10, Issue 4, 2009, Pages 308-338

  Kanwar, Jagat R ^a   Kanwar, Rupinder K ^a   Sun, Xueying ^b,c   Punj, Vasu ^d   Matta, H ^d   Morley, Somasundaram M ^e   Parratt, Andrew ^a   Puri, Munish ^f   Sehgal, Rakesh ^g  

^a Institute for Technology Research and Innovation   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e DEAKIN UNIVERSITY   (Australia)

^f PUNJABI UNIVERSITY   (India)

^g POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

And anti inflammation; Anti cancer; Anti infection; Bioactive milk proteins peptides; Health benefit

Indexed keywords

ACICLOVIR; ALPHA CASEIN; ALPHA LACTALBUMIN; APOLACTOFERRIN; CALCIUM; CASEIN; CASEIN PHOSPHOPEPTIDE; CEPHALOSPORIN; COLOSTRININ; CONJUGATED LINOLEIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPROTEIN; IMMUNOGLOBULIN; ISRACIDIN; LACTOFERRAMPIN; LACTOFERRICIN; LACTOFERRICIN B; LACTOFERRIN; LACTOPEROXIDASE; LYSOZYME; METALLOPROTEIN; MILK PROTEIN; OLIGOSACCHARIDE; OPIATE PEPTIDE; PENICILLIN G; PHOSPHOPEPTIDE; PLACEBO; POLYPEPTIDE; PROLINE RICH PROTEIN; TALACTOFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTERY THROMBOSIS; BACTEREMIA; BACTERIAL INFECTION; BIOLOGICAL ACTIVITY; BIOTECHNOLOGY; BLOOD TOXICITY; BREAST MILK; CANDIDIASIS; CLINICAL TRIAL; COLITIS; COLON CARCINOMA; DIARRHEA; DRUG POTENTIATION; FOOD COMPOSITION; HELICOBACTER INFECTION; HEPATITIS C; HERPES SIMPLEX; HUMAN; HYPERTENSION; IMMUNOMODULATION; KIDNEY INFECTION; KLEBSIELLA PNEUMONIAE INFECTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MASTITIS; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NONHUMAN; NUTRITIONAL HEALTH; NUTRITIONAL VALUE; REVIEW; SALMONELLOSIS; STAPHYLOCOCCUS INFECTION; STOMACH ULCER; TINEA PEDIS; TOXOPLASMOSIS; URINARY TRACT INFECTION;

ANIMALS; BIOTECHNOLOGY; HEALTH; HUMANS; MILK; MILK PROTEINS; PEPTIDES;

ADENOVIRIDAE; ANIMALIA; ROTAVIRUS;

EID: 70349512735     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920309788922234     Document Type: Review

References (267)

1. Carbonare, S. B.; Silva, M. L.; Palmeira, P.; Carneiro-Sampaio, M. M. Human colostrum IgA antibodies reacting to enteropathogenic Escherichia coli antigens and their persistence in the faeces of a breastfed. J. Diarrhoeal Dis. Res., 1997, 15, 53-58.
2. Kanwar, J. R.; Palmano, K. P.; Sun, X.; Kanwar, R. K.; Gupta, R.; Haggarty, N.; Rowan, A.; Ram, S.; Krissansen, G. W. 'Ironsaturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol. Cell Biol., 2008, 86, 277-88.
3. Hanson, L, A. Breastfeeding provides passive and likely longlasting active immunity. Ann. Allergy Asthma. Immunol., 1998, 81, 523-33.
4. Korhonen, H.; Marnila, P.; Gill, H. S. Bovine milk antibodies for health. Brit. J. Nutr., 2000, 48 (Suppl. 1), S135-S146.
5. Kanwar, R. K.; MacGibbon, A. K.; Black, P. N.; Kanwar, J. R.; Rowan, A.; Vale, M.; Krissansen, G. W. Bovine milk fat enriched in conjugated linoleic and vaccenic acids attenuates allergic airway disease in mice. Clin. Exp. Allergy, 2008, 38, 208-18.
6. Hartmann, P. B.; Rattigan, S.; Saint, L.; Supriyana, O. Variation in the yield and composition of human milk. Oxf Rev. Reprm. Biol., 1985, 7, 118-167.
7. Sanchez-Pozo, A.; Lopez, J.; Pita, M. L.; Izquierdo, A.; Guerrero, E.; Sanchez-Medina, F.; Martinez Valverde, A.; Gil, A. Changes in the protein fractions of human milk during lactation. Ann. Nutr. Metab., 1986, 30, 15-20.
8. Goldman, A. S. The immune system of human milk: antimicrobial, antiinflammatory and immunomodulating properties. Pediatr. Infect. Dis. J., 1993, 12, 664-671.
9. Lonnerdal, B.; Iyer, S. Lactoferrin: molecular structure and biological function. Ann. Rev. Nutr., 1995, 15, 93-110.
10. Gutteberg, T. J.; Rokke, O.; Andersen, O.; Jorgensen, T. Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxemia: an early defence mechanism. Scand. J. Infect. Dis., 1989, 21, 709-715.
11. Sanchez, L.; Calvo, M.; Brock, J. H. Biological role of lactoferrin. Arch. Dis. Child., 1992, 61, 657-661.
12. Baveye, S.; Elass, E.; Mazurier, J.; Spik, G.; Legrand, D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin. Chem. Lab. Med., 1999, 37, 281-286.
13. Naidu, S. S.; Svensson, L. J.; Kishore, A. R.; Naidu, A.S. Relationship between antibacterial activity and porin binding of lactoferrin Milk-derived proteins and peptides of potential therapeutic and nutritive value in Escherichia coli and Salmonella typhimurium. Antimicrob. Agents Chemother., 1993, 37, 240-245.
14. Sallmann, F. R.; Baveye-Descamps, S.; Pattus, F.; Salmon, V.; Branza, N.; Spik, G.; Legrand, D. Porins OmpC and PhoE of Escherichia coli as specific cell surface targets of human lactoferrin. Binding characteristics and biological effects. J. Biol. Chem., 1999, 274, 16107-16114.
15. Jensen, R. G., Newburg, D. S. In Bovine milk lipids, Jensen, R.G., Ed, Handbook of milk composition. Academic Press: USA, 1995, pp. 543-575.
16. Holt, C.; Wahlgren, N. M.; Drakenberg, T. Ability of a β-casein phosphopeptide to modulate the precipitation of calcium phosphate by forming amorphous dicalcium phosphate nanoclusters. Biochem. J., 1996, 314, 1035-1039.
17. McMahon, D. J.; Oommen, B. S. Supramolecular structure of the casein micelle. J. Dairy Sci., 2008, 91, 5.
18. Home, D. S. Casein structure, self-assembly and gelation. Curr. Opin. Colloid Interface Sci., 2002, 7, 456-461.
19. USDA National Nutrient Database for Standard Reference. http://www.nal.usda.gov/fnic/foodcomp/Data/ (accessed September 3, 2007).
20. Haug, A.; Høstmark, A. T.; Harstad, O. M. Bovine milk in human nutrition - a review. Lipids Health Dis., 2007, 25, 6-25.
21. Grundy, S. M. Influence of stearic acid on cholesterol metabolism relative to other long-chain fatty acids. Am. J. Clin. Nutr., 1994, 60, 986S-990S.
22. Thormar, H.; Isaacs, E. E.; Kim, K. S.; Brown, H. R. Inactivation of visna virus and other enveloped viruses by free fatty acids and monoglycerides. Ann. NY Acad. Sci., 1994, 724, 465-71.
23. German, J.B. Food processing and lipid oxidation. Adv. Exp. Med. Biol., 1999, 459, 23-50.
24. Mensink, R. P.; Zock, P. L.; Kester, A. D.; Katan, M. B. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a metaanalysis of 60 controlled trials. Am. J. Clin. Nutr., 2003, 77, 1146-1155.
25. Sun, C. Q.; O'Connor, C. J.; Roberton, A. M. The antimicrobial properties of milkfat after partial hydrolysis by calf pregastric lipase. Chem. Biol. Interact., 2002, 140, 185-198.
26. Schuster, G. S.; Dirksen, T. R.; Ciarlone, A. E.; Burnett, G. W.; Reynolds, M. T. Anticaries and antiplaque potential of free-fatty acids in vitro and in vivo. Pharmacol. Ther. Dent., 1980, 5, 25-33.
27. Sun, C. Q.; O'Connor, C. J.; Roberton, A. M. The products from lipase-catalysed hydrolysis of bovine milkfat kill Helicobacter pylori in vitro. FEMS Immunol. Med. Microbiol., 2003, 36, 9-17.
28. Henry, G. E.; Momin, R. A.; Nair, M. G.; Dewitt, D. L. Antioxidant and cyclooxygenase activities of fatty acids found in food. J Agric. Food Chem., 2002, 50, 2231-2234.
29. Chi, D.; Nakano, M.; Yamamoto, K. Milk consumption does not affect body mass index but may have an unfavorable effect on serum total cholesterol in Japanese adults. Cent. Eur. J. Public Health, 2004, 12, 84-87.
30. Mensink, R. P.; Katan, M. B. Effect of dietary fatty acids on serum lipids and lipoproteins: a meta- analysis of 27 trials. Arterioscler. Thromb., 1992, 12, 911-919.
31. Hegsted, D. M.; Ausman, L. M.; Johnson, J. A.; Dallal, G. E. Dietary fat and serum lipids: an evaluation of the experimental data. Am. J. Clin. Nutr., 1993, 57, 875-883.
32. Sandstrom, B.; Marckmann, P.; Bindslev, N. An eight-month controlled study of a low-fat/high-fibre diet: effects on blood lipids and blood pressure in healthy young subjects. Eur. J. Clin. Nutr., 1992, 46, 95-109.
33. Marckmann, P.; Sandstrom, B.; Jespersen, J. Low-fat high-fiber diet favorably affects several independent risk markers of ischemic heart disease: observations on blood lipids, coagulation, and fibrinolysis from a trial of middle-aged Danes. Am. J. Clin. Nutr., 1994, 59, 935-939.
34. Seidel, C.; Deufel, T.; Jahreis, G. Effects of fat-modified dairy products on blood lipids in humans in comparison with other fats. Ann. Nutr. Metab., 2005, 49, 42-48.
35. Bosaeus, I. Milk and cholesterol (in Swedish with English summary). Vår Föda., 1991, 43, 98-101.
36. Eichholzer, M., Stahelin, H. Milk drinking, ischaemic heart disease and ischaemic stroke Int. J. Vitam. Nutr. Res., 1993, 63, 158-167.
37. Elwood, P. C.; Pickering, J. E.; Hughes, J.; Fehily, A. M.; Ness, A. R. Milk drinking, ischaemic heart disease and ischaemic stroke II: evidence from cohort studies. Eur. J. Clin. Nutr., 2004, 58, 718-724.
38. Stähelin, H. B. In Nutritional factors Correlating with Cardivascular Disease: Results of the Basel Study. Somogyi, J.C.; Biro, G. Y.; Hotzel, D. Eds. Nutrition and Cardiovascular Risks Bibl Nutr Dieta Basel, Karger. 1992, pp. 49, 24-35.
39. Willett, W. C.; Stampfer, M. J.; Manson, J. E.; Colditz, G. A.; Speizer, F. E.; Rosner, B. A.; Sampson, L. A.; Hennekens, C. H. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet, 1993, 341, 581-535.
40. Fehily, A. M.; Yarnell, J. W.; Sweetnam, P. M.; Elwood, P. C. Diet and incident ischaemic heart disease: the Caerphilly Study. Br. J. Nutr., 1993, 69, 303-314.
41. Ness, A. R.; Smith, G. D.; Hart, C. J. Milk, coronary heart disease and mortality. Epidemiol. Commun. Health, 2000, 55, 379-382.
42. Smedman, A. E.; Gustafsson, I. B.; Berglund, L. G.; Vessby, B. O. Pentadecanoic acid in serum as a marker for intake of milk fat: relations between intake of milk fat and metabolic risk factors. Am. J. Clin. Nutr., 1999, 69, 22-29.
43. Warensjo, E.; Jansson, J. H.; Berglund, L.; Boman, K.; Ahren, B.; Weinehall, L.; Lindahl, B.; Hallmans, G.; Vessby, B. Estimated intake of milk fat is negatively associated with cardiovascular risk factors and does not increase the risk of a first acute myocardial infarction. A prospective case-control study. Br. J. Nutr., 2004, 91, 635-642.
44. Biong, A. S.; Veierod, M. B.; Ringstad, J.; Thelle, D. S.; Pedersen, J. I. Intake of milk fat, reflected in adipose tissue fatty acids and risk of myocardial infarction: a case-control study. Eur. J. Clin. Nutr., 2006, 60, 236-244.
45. Biong, A. S.; Rebnord, H. M.; Fimreite, R. L.; Trygg, K. U.; Ringstad, J.; Thelle, D. S.; Pedersen, J. I. Intake of dairy fat and dairy products, and risk of myocardial infarction: a case-control study. Int. J. Food Sci. Nutr., 2008, 59(2), 155-165.
46. Sjogren, P.; Rosell, M.; Skoglund-Andersson, C.; Zdravkovic, S.; Vessby, B.; de Faire, U.; Hamsten, A.; Hellenius, M. L.; Fisher, R. M. Milk-derived fatty acids are associated with a more favorable LDL particle size distribution in healthy men. J. Nutr., 2004, 134, 1729-1735.
47. German, J. B.; Dillard, C. J. Saturated fats: what dietary intake? Am. J. Clin. Nutr., 2004, 80, 550-559.
48. Kris-Etherton, P. M.; Pearson, T. A.; Wan, Y.; Hargrove, R. L.; Moriarty, K.; Fishell, V.; Etherton, T. D. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am. J. Clin. Nutr., 1999, 70, 1009-1015.
49. Ip C. Review of the effects of trans fatty acids, oleic acid, n-3 polyunsaturated fatty acids, and conjugated linoleic acid on mammary carcinogenesis in animals. Am. J. Clin. Nutr., 1997, 66, 1523S-1529S.
50. Haug, A.; Hallaq, H.; Leaf, A. In Potential Antiatherogenic Effects of Omega-3 Fatty Acids. Neri Serneri, G. G.; Gensini, G. F.; Abbate, R.; Prisco, D., Eds. Thrombosis, an update. Scientific press. Florence; 1992, pp. 361-372.
51. Jump, D. B.; Clarke, S. D. Regulation of gene expression by dietary fat. Ann. Rev. Nutr., 1999, 19, 63-90
52. Bagga, D.; Wang, L.; Farias-Eisner, R.; Glaspy, J. A.; Reddy, S. T. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc. Natl. Acad. Sci. USA, 2003, 100, 1751-1756
53. Wahle, K. W.; Heys, S. D.; Rotondo, D. Conjugated linoleic acids: are they beneficial or detrimental to health? Prog. Lipid Res., 2004, 43, 553-587
54. Delmonte, P.; Kataok, A.; Corl, B. A.; Bauman, D. E.; Yurawecz, M. P. Relative retention order of all isomers of cis/trans conjugated linoleic acid FAME from the 6,8- to 13,15-positions using silver ion HPLC with two elution systems. Lipids, 2005, 40, 509-514
55. Ding, S. T.; McNeel, R. L.; Mersmann, H. J. Modulation of adipocyte determination and differentiation-dependent factor I by selected polyunsaturated fatty acids. In Vitro. Cell Dev. Biol. Anim., 2002, 38, 352-357
56. Roche, H. M.; Noone, E.; Sewter, C.; Mc Bennett, S.; Savage, D.; Gibney, M. J.; O'Rahilly, S.; Vidal-Puig, A. J. Isomer-dependent metabolic effects of conjugated linoleic acid: insights from molecular markers sterol regulatory element-binding protein-1c and LXRalpha. Diabetes, 2002, 51, 2037-2044
57. Stene, O.; Thuen, E.; Lindstad, P.; Haug, A. Husdyrforsøksmøtet, Norway. 2002, pp. 557-560.
58. Bell, J. A.; Griinari, J. M.; Kennelly, J. J. Effect of safflower oil, flaxseed oil, monensin, and vitamin E on concentration of conjugated linoleic acid in bovine milk fat. J. Dairy Sci., 2006, 89, 733-748.
59. Terpstra, A. H. Effect of conjugated linoleic acid on body composition and plasma lipids in humans: an overview of the literature. Am. J. Clin. Nutr., 2004, 79, 352-361.
60. Tricon, S.; Burdge, G. C.; Kew, S.; Banerjee, T.; Russell, J. J.; Jones, E. L.; Grimble, R. F; Williams, C. M.; Yaqoob, P.; Calder, P.C. Opposing effects of cis-9,trans-11 and trans-10,cis-12 conjugated linoleic acid on blood lipids in healthy humans. Am. J. Clin. Nutr., 2004, 80, 614-620.
61. Valeille, K.; Gripois, D.; Blouquit, M, F.; Souidi, M.; Riottot, M.; Bouthegourd, J. C.; Serougne, C.; Martin, J. C. Lipid atherogenic risk markers can be more favourably influenced by the cis-9,trans- 11-octadecadienoate isomer than a conjugated linoleic acid mixture or fish oil in hamsters. Br. J. Nutr., 2004, 91, 191-199.
62. Gavino, V. C.; Gavino, G.; Leblanc, M. J.; Tuchweber, B. An isomeric mixture of conjugated linoleic acids but not pure cis-9, trans-11-octadecadienoic acid affects body weight gain and plasma lipids in hamsters. J. Nutr., 2000, 130, 27-29.
63. Benito, P.; Nelson, G. J.; Kelly, D. S.; Bartolini, G.; Schmidt, P. C.; Simon, V. The effect of conjugated linoleic acid on plasma lipoproteins and tissue fatty acid composition in humans. Lipids, 2001, 36, 229-236.
64. Thomas Yeung C. H.; Yang, L.; Huang Y.; Wang J.; Chen Z. Y. Dietary conjugated linoleic acid mixture affects the activity of intestinal acyl coenzyme A: cholesterol acyltransferase in hamsters. Br. J. Nutr., 2000, 84, 935-941.
65. Ostrowska, E.; Cross, R. F.; Muralitharan, M.; Bauman, D. E.; Dunshea, F. R. Effects of dietary fat and conjugated linoleic acid on plasma metabolite concentrations and metabolic responses to homeostatic signals in pigs. Br. J. Nutr., 2002, 88, 625-634.
66. Ha, Y. L.; Grimm, N. K.; Pariza, M. W. Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid. Carcinogenesis, 1987, 8, 1881-1887.
67. Ledoux, M.; Chardigny, J. M.; Darbois, M.; Soustre, Y.; Sebedio, J. L.; Laloux, L. J. Fatty acid composition of French butters with special emphasis on conjugated linoleic acid (CLA) isomers. J. Food Comp. Anal., 2005, 18, 409-425.
68. Precht, D.; Molktentin, J. Rapid analysis of isomers of trans-octadecenoic acid in milk fat. Int. Dairy J., 1996, 6, 791-809.
69. Pan, X. L.; Izumi, T. Variation of the ganglioside compositions of human milk, cow's milk and infant formulas. Early Hum. Dev., 2000, 57, 25-31.
70. Spitsberg, V. L. Invited review: bovine milk fat globule membrane as a potential nutraceutical. J. Dairy Sci., 2005, 88, 2289-2294.
71. Spitsberg, V. L.; Gorewit, R. C. Breast ovarian cancer susceptibility protein (BRCA1) in milk, tissue and cells. J Dairy Sci., 1997, 80 (Suppl. 1), 60.
72. Krum, S. A.; Womack, J. E.; Lane, T. F. Bovine BRCA1 shows classic responses to genotoxic stress but low in vitro transcriptional activation activity. Oncogene, 2003, 22, 6032-6044.
73. Rodriguez, M.; Yu, X.; Chen, J.; Songyang, Z. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains. J. Biol. Chem., 2003, 278, 52914-52918.
74. Daniels, M. J.; Wang, Y.; Lee, M.; Venkitaraman, A. R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science, 2004, 306, 876-879.
75. Howard, A. N.; Marks, J. Effect of milk products on serum-cholesterol. Lancet, 1979, 2, 957.
76. Arai, T.; Takahashi, M.; Kamata, S.; Sako, T. Changes in activities of enzymes related to malate-aspartate shuttle in leukocytes from dogs given a herb supplement. J. Vet. Med. Sci., 2001, 63, 695-697.
77. Noh, S. K.; Koo, S. L. Milk sphingomyelin is more effective than egg sphingomyelin in inhibiting intestinal absorption of cholesterol and fat in rats. J. Nutr., 2004, 134, 2611-2616.
78. Wang, X.; Hirmo, S.; Willén, R.; Wadström, T. Inhibition of Helicobacter pylori infection by bovine milk glycoconjugates in a BAlb/cA mouse model. J. Med. Microbiol., 2001, 50, 430-435.
79. Guggenmos, J.; Schubari, A. S.; Ogg, S.; Anderson, M.; Olsson, T.; Mather, I. H.; Linington, C. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J. Immunol., 2004, 172, 661-668.
80. Mather, I. H. A review and proposed nomenclature for major proteins of the milk-fat globule membrane. J Dairy Sci., 2000, 83, 203-247.
81. Jenness, R. Composition and characteristics of goat milk: review 1968-1979 J. Dairy Sci., 1980, 63, 1605-1630.
82. Bernard, L.; Leroux, C.; Chilliard, Y. Expression and nutritional regulation of lipogenic genes in the ruminant lactating mammary gland. Adv. Exp. Med Biol., 2008, 606, 67-108.
83. Struff, W. G.; Sprotte, G. Bovine colostrum as a biologic in clinical medicine: a review. Part I: biotechnological standards, pharmacodynamic and pharmacokinetic characteristics and principles of treatment. Int. J. Clin. Pharmacol. Ther., 2007, 45, 193-202.
84. Rinaldi, L.; Veneziano, V.; Cringoli, G. Dairy goat production and the importance of gastrointestinal strongyle parasitism. Trans. R. Soc. Trop. Med. Hyg., 2007, 101, 745-746.
85. Eigenmann, P. A. The spectrum of cow's milk allergy. Pediatr Allergy Immunol., 2007, 18, 265-271.
86. Johnson, M. E.; Lucey, J. A. Major technological advances and trends in cheese. J. Dairy Sci., 2006, 89, 1174-1178.
87. Adamson, N. J.; Reynolds, E. C. Characterization of tryptic casein phosphopeptides prepared under industrially relevant conditions Biotechnology Bioeng., 1995, 45, 196-204.
88. Tomita, M.; Bellamy, W.; Takase, M.; Yamauchi, K. Wakabayashi, H.; Kawase, K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J. Dairy Sci. 1991, 74, 4137-4142.
89. Nibbering, P. H.; Ravensbergen, F.; Welling, M. M.; van Berkel, L. A.; van Berkel, P. H. C.; Pauwels, E. K. J.; Nuijens, J. H. Human Lactoferrin and peptides derived from its n terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun., 2001, 69, 1469-1476.
90. Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H. Kawase, K.; Tomita, M. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta, 1992, 1121, 130-136.
91. Bellamy, W. R.; Wakabayashi, H.; Takase, M.; Kawase, K. Shimaniura, S.; Tomita, M. Role of cell-binding in the antibacterial mechanism of lactoferricin B. Br. J Appl. Bacteriol., 1993, 75, 478-484.
92. Jonasch, E.; Stadler, W. M.; Bukowski, R. M.; Hayes, T. G. Varadhachary, A.; Malik, R.; Figlin, R. A.; Srinivas, S. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer, 2008, 113, 72-77.
93. Hartog, A.; Leenders, I.; van der Kraan, P. M.; Garssen, J. Anti-inflammatory effects of orally ingested lactoferrin and glycine in different zymosan-induced inflammation models: evidence for synergistic activity. Int. Immunopharmacol., 2007, 15, 1784-1792.
94. Dyer, A. R.; Burdock, G. A.; Carabin, I. G.; Haas, M. C.; Boyce, J. Alsaker, R.; Read, L. C. in vitro and in vivo safety studies of a proprietary whey extract. Food Chem. Toxicol., 2008, 46, 1659-1665.
95. Brock, J. H. The physiology of lactoferrin. Biochem. Cell Biol., 2002, 80, 1-6.
96. Tomita, M.; Wakabayashi, H.; Shin, K.; Yamauchi, K.; Yaeshima, T.; Iwatsuki, K. Twenty-five years of research on bovine lactoferrin applications. Biochimie, 2009, 91, 52-57.
97. Zhang, G. H.; Mann, D. M.; Tsai, C. M. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect. Immun., 1999, 7, 1353-1358.
98. van der Kraan, M. I.; Groenink, J.; Nazmi, K.; Veerman, E. C. Bolscher, J. G.; Nieuw Amerongen, A. V. Lactofenumpin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides, 2004, 25, 177-183.
99. Kawasaki, Y.; Tazume, S.; Shimizu, K.; Matsuzawa, H.; Dosako, S.; Isoda, H4 Tsukiji, M.; Fujimura, R.; Muranaka, Y.; Isihida, H Inhibitory effects of bovine lactoferrin on the adherence of enterotoxigenic Escherichia coli to host cells. Biosci. Bioteclnol. Biochem., 2000, 64, 348-354.
100. de Araújo, A. N.; Giugliano, L. G. Lactoferrin and free secretory component of human milk inhibit the adhesion of enteropathogenic Escherichia coli to HeLa cells. BMC Microbiol., 2001, 1, 25.
101. Qiu, J.; Hendrixson, D. R.; Baker, E. N.; Murphy, T. F.; Geme, J W.; Plaut, A. G. Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc Natl. Acad. Sci. USA, 1998, 95, 12641-12646.
102. Weinberg, E. D. Iron, infection, and neoplasia. Clin. Physiol. Biochem., 1986, 4, 50-60.
103. Touyz, R. M. Oxidative stress and vascular damage in hypertension. Curr. Hypertens. Rep., 2000, 2, 98-105.
104. Marnett, L. J. Oxyradicals and DNA damage. Carcinogenesis, 2000, 21, 361-370.
105. Misonou, H.; Morishima-Kawashima, M.; Ihara, Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry, 2000, 39, 6951-6959.
106. Ruef, J.; Petrak, K.; Nordt, T. K.; Runge, M. S.; Kübler W.; Bode, C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb. Haemost., 1999, 82 (Suppl I), 32-37.
107. Zagulski, T.; Lipiński, P.; Zagulska, A.; Jarzbek, Z. Antibacterial system generated by lactoferrin in mice in vivo is primarily a killing system. Int. J. Exp. Pathol., 1998, 79, 117-123.
108. Zagulski, T.; Jarzabek, Z.; Zagulska, A.; Jaszczak, M.; Kocbanowska, I. E.; Zimecki, M. Lactoferrin stimulates killing and clearance of bacteria but does not prevent mortality of diabetic mice. Arch. Immunol. Ther. Exp., 2001, 49, 431-438.
109. Håversen, L. A.; Engberg, I.; Baltzer, L.; Dolphin, G.; Hanson, L. A.; Mattsby-Baltzer, I. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect. Immun., 2000, 68, 5816-5823.
110. Zimecki, M.; Artym, J.; Chodaczek, G.; Kociba, M.; Kruzel, M. L. Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm. Res., 2004, 53, 292-296.
111. Sawatzki, G.; Rich, I. N. Lactoferrin stimulates colony stimulating factor production in vitro and in vivo. Blood cells, 1989, 15, 371-385.
112. Trümpler U.; Straub, P. W.; Rosenmund, A. Antibacterial prophylaxis with lactoferrin in neutropenic patients. Eur. J. Clin. Microbiol. Infect., 1989, 8, 310-313.
113. Griffiths, E. A.; Duffy, L. C.; Schanbacher, F. L.; Dryja, D.; Leavens, A.; Neiswander, R. L.; Qiao, H.; DiRienzo, D.; Ogra, P. In vitro growth responses of bifidobacteria, and enteropathogens to bovine and human lactoferrin. Dig. Dis. Sci., 2003, 48, 1324-1332.
114. Leitch, E. C.; Willcox, M. D. Lactoferrin increases the susceptibility of S. epidermidis biofilms to lysozyme and vancomycin. Curr. Eye Res., 1999, 19, 12-19.
115. Diarra, M. S.; Petitclere, D.; Lacasse, P. Effect of lactoferrin in combination with penicillinon the morphology and the physiology of Staphylococcus aureus isolated from bovine mastitis. J Dairy Sci., 2002, 85, 1141-1149.
116. Miyazaki, S.; Harada, Y.; Tsuji, A.; Goto, S. in vivo combined effects of lactoferrin and drugs on bacterial infections in mice. Chemotherapy, 1991, 29, 929-835.
117. Dhaenens, L.; Szczebara, F.; Husson, M. O. Identification, characterization, and immunogenicity of the lactoferrin-binding protein from Helicobacter pylori. Infect. Immun., 1997, 65, 514-518.
118. Mickelsen, P. A.; Blackman, E.; Sperling, P. F. Ability of Neisseria gonorrhoeae, Neisseria meningitidis, and commensal Neisseria species to obtain iron from lactoferrin. Infect. Immun., 1982, 35, 915-920,
119. Nikawa, H.; Samaranayakp, L. P.; Tenovuo, J.; Pang, K. M.; Hamada, T. The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch. Oral Biol., 1993, 38, 1057-1063.
120. Soukka, T.; Tenovuo,, J.; Lenander-Lumikari, M. Fungicidal effect of human lactoferrin against Candida albicans. FEAE Microbial. Lett., 1992, 69, 223-228.
121. Lupetti, A.; Paulusma-Annema, A.; Welling, M. M.; Senesi, S.; van Dissel, J. T.; Nibbering, P. H. Fungicidal effect of human lactoferrin against Candida albicans. Antimicrob. Agents Chemother., 2000, 44, 3257-3263.
122. Andersson, Y.; Lindquist, S.; Lagerqvist, C.; Hemell, O. Lactoferrin is responsible for the fungistatic effect of human milk. Early Hum. Dev., 2000, 59, 95-105.
123. Wakabayashi, H.; Uchida, K.; Yamauchi, K.; Teraguchi, S.; Hayasawa, H.; Yamaguchi, H. Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. J. Antimicrob. Chemother., 2000, 46, 595-602.
124. Wakabayashi, H.; Takakura, N.; Yamauchi, K.; Teraguchi, S.; Uchida, K.; Yamaguchi, H.; Tamura, Y. Effect of lactoferrin feeding on the host antifungal response in guinea-pigs infected or immunised with Trichophyton mentagrophytes. J Med. Microbiol., 2002, 51, 844-850.
125. Yamauchi, K.; Hiruma, M.; Yamazaki, N.; Wakabayashi, H.; Kuwata, H.; Teraguchi, S.; Hayasawa, H.; Suegara, N.; Yamaguchi, H. Oral administration of bovine lactoferrin for treatment of tinea pedis: a placebotcontrofled, double-blind study. Mycoses, 2000, 43, 197-202.
126. Kuipers, M. E.; Heegsma, J.; Bakker, H. I.; Meijer, D. K.; Swart, P. J.; Frijlink, E. W.; Eissens, A. C.; de Vries-Hospers, H. G.; van den Berg, J. J. Design and fungicidal activity of mucoadhesive lactoferrin tablets for the treatment of oropharyngeal candidosis. Drug, 2002, 9, 31-38.
127. Wakabayashi, H.; Abe, S.; Okutomi, T.; Tansho, S.; Kawase, K.; Yamaguchi, H. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antiftingal agents. Microbiol. Immunol., 1996, 40, 821-825.
128. Lupetti, A.; Paulusma-Annema, A.; Welling, M. M.; Dogterom-Ballering, H.; Brouwer, C. P.; Senesi, S.; Van Dissel, J. T.; Nibbering, P. H. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob. Agents Chemother., 2003, 47, 262-267.
129. Isamida, T.; Tanaka, T.; Omata, Y.; Yamauchi, K.; Shimazaki, K.; Saito, A. Protective effect of lactoferricin against Toxoplasma gondii infection in mice. J. Fet. Med Sci., 1998, 60, 241-244.
130. Tanaka, T.; Omata, Y.; Narisawa, M.; Saito, A.; Shimazaki, K.; Igarashi, I.; Hirumi, H.; Suzuki, N. Growth inhibitory effect of bovine lactoferrin on Toxoplasma gondii tachyzoites in murine macrophages: role of radical oxygen and inorganic nitrogen oxide in Toxoplasma growth-inhibitory activity. Vet. Parasitol., 1997, 68, 27-33.
131. Tanaka, T.; Omata, Y.; Isamida, T.; Saito, A.; Shimazaki, K.; Yamauchi, K.; Suzuki, N. Growth inhibitory effect of bovine lactoferrin to Toxoplasma gondii tachyzoites in murine macrophages: tyrosine phosphorylation in murine macrophages induced by bovine lactoferrin. J, Vet. Med Sci., 1998, 60, 369-371
132. Fritsch, G.; Sawatzki, G.; Treumer, J.; Jung, A.; Spira, D. T. Plasmodium. falciparum: inhibition in vitro with lactoferrin, desferrifenithiocin, and desferricrocin. Exp. Parasitol., 1987, 63, 1-9.
133. Lima, M. F Kierszenbaum, F. Lactoferrin effects on phagocytic cell function. 1. Increased uptake and killing of an intracellular parasite by murine macrophages and human monocytes. J. Immunol., 1985, 134, 4176-4183.
134. Peterson, K. M.; Alderete, 1. F. Iron uptake and increased intracellular enzyme activity follow host lactoferrin binding by Trichomonas vaginalis receptors. J. Exp. Med., 1984, 160, 398-410.
135. Wilson, M. E.; Vorhies, R. W.; Andersen, K. A.; Britigan, B. E. Acquisition of iron from transferrin and lactoferrin by the protozoan Leishmania chagasi. Infect. Immun., 1994, 62, 3262-3269.
136. Ikeda, M.; Nozaki, A.; Sugiyama, K.; Tanaka, T.; Naganuma, A.; Tanaka, K.; Sekihara, H.; Shimotohno, K., Saito, M.; Kato, N. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res., 2000, 66, 51-63.
137. Ikeda, M.; Sugiyama, K.; Tanaka, T.; Tanaka, K.; Sekihara, H.; Shimotohno, K.; Kato, N. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human bepatocytes. Biochem. Biophys. Res. Commun., 1998, 245, 549-553.
138. Nozaki, A.; Ikeda, M.; Naganuma, A.; Nakamura, T.; Inudoh, M.; Tanaka, K.; Kato, N. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J. Biol. Chem., 2003, 278, 10162-10173.
139. Nozaki, A.; Tanaka, K.; Naganuma, A.; Kato, N. Recent advances of basic research and clinical application of lactoferrin as an antiviral reagent against chronic hepatitis C. Nippon Rinsho, 2002, 60, 819-829.
140. Puddu, P.; Borghi, P.; Gessani, S.; Valenti, P.; Belardelli, F.; Seganti, L. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type I infection. Int. J. Biochem. Cell Biol., 1998, 30, 1055-1062.
141. Groot, F.; Geijtenbeek, T. B.; Sanders, R. W.; Baldwin, C. E.; Sanchez-Hernandez, M.; Floris, R.; van Kooyk, Y.; de Jong, E. C.; Berkhout, B. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN - gp 120 interaction. J. Virol., 2005, 79, 3009-15.
142. Berkhout, B.; van Wamel, J. L.; Beljaars, L.; Meijer, D. K.; Visser, S.; Floris, R. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res., 2002, 55, 341-355.
143. Drobni, P.; Näslund J.; Evander, M. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res., 2004, 64, 63-68.
144. Marchetti, M.; Trybala, E.; Superti, F.; Johansson, M.; Bergström, T. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology, 2004, 318, 405-413.
145. DiBiase, A. M.; Pietrantoni, A.; Tinari, A.; Siciliano, R.; Valenti, P.; Antonini, G.; Seganti, L.; Superti, F. Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J. Med. Virol., 2003, 69, 495-502.
146. Andersen, J. H.; Osbakk, S. A.; Vorland, L. H.; Traavik, T.; Gutteberg, T. J. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res., 2001, 51, 141-149.
147. Superti, F.; Siciliano, R.; Rega, B.; Giansanti, F.; Valenti, P.; Antonini, G. Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochim. Biophys. Acta., 2001, 1528, 107-115.
148. Shimizu, K.; Matsuzawa, H.; Okada, K.; Tazume, S.; Dosako, S.; Kawasaki, Y.; Hashimoto, K.; Koga, Y. Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell-dependent augmentation of natural killer cell activity. Virol., 1996, 141, 1875-1889.
149. Andersen, J. H.; Jenssen, H.; Gutteberg, T. J. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res., 2003, 58, 209-215.
150. Tanaka, T.; Nakatani, S.; Xuan, X.; Igarashi, H. I.; Shimazaki, K. Antiviral activity of lactoferrin against canine herpesvirus. Antiviral Res., 2003, 60, 193-199.
151. McCann, K. B.; Lee, A.; Wan, J.; Roginski, H.; Coventry, M. J. The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. Microbiol., 2003, 95, 1026-1033.
152. Yang, N.; Stensen, W.; Svendsen, J. S.; Rekdal, Ø. Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J. Pept. Res., 2002, 60, 187-197.
153. Eliassen, L. T.; Berge, G.; Sveinbjomsson, B.; Svendsen, J. S.; Vorland, L. H.; Rekdal, Ø. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res., 2002, 22, 2703-2710.
154. Ligo, M.; Kuhara, T.; Ushida, Y.;.Sekine, K.; Moore, M. A.; Tsuda, H. Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin. Exp. Metastasis, 1990, 17, 35-40.
155. Bezault, J.; Bhimani, R.; Wiprovnick, J.; Furmanski, P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res., 1994, 54, 2310-2312.
156. Yoo, Y. C.; Watanabe, S.; Watanabe, R.; Hata, K.; Shimazaki, K.; Azuma, I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res., 1997, 88, 184-190.
157. Shimamura, M.; Yamamoto, Y.; Ashino, H.; Oikawa, T.; Hazato, T.; Tsuda, H.; Ligo, M. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int. J. Cancer, 2004, 111, 111-116.
158. Zimecki, M.; Mazurier, J.; Machnicki, M.; Wieczorek, Z.; Montreuil, J.; Spik, G. Immunostimulatory activity of lactotransferrin and maturation of CD4- CD8- murine thymocytes. Immunol. Lett., 1991, 30, 119-123.
159. Zimecki, M.; Mazurier, J.; Spik, G.; Kapp, J.A. Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology, 1995, 86, 122-127.
160. Zimecki, M.; Kruzel, M. L. Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice. Immunol. Lett., 2000, 14, 183-188.
161. Debbabi, H.; Dubarry, M.; Rautureau, M.; Tome, D. Bovine lactoferrin induces both mucosal and systemic immune response in mice. J. Dairy Res., 1998, 65, 283-293.
162. Zimecki, M.; Machnicki, M. Lactoferrin inhibits the effector phase of the delayed type hypersensitivity to sheep erythrocytes and inflammatory reactions to M bovis (BCG). Arch. Immunol. Ther. Exp., 1994, 42, 171-177.
163. Zimecki, M.; Mazurier, J.; Spik, G.; Kapp, J. A. Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch. Immunol. Ther. Exp., 1996, 44, 51-56.
164. Zimecki, M.; Wieczorek, Z.; Mazurier, J.; Spik, G. Lactoferrin lowers the incidence of positive Coombs' test in New Zealand black mice. Arch. Immunol. Ther. Exp., 1995, 43, 207-209.
165. Artym, J.; Zimecki, M.; Kruzel, M. L. Reconstitution of the cellular immune response by lactoferrin in cyclophosphamide-treated mice is correlated with renewal of T cell compartment. Immunobiology, 2003, 207, 197-205.
166. Artym, J.; Zimecki, M.; Paprocka, M.; Kruzel, M. L. Orally administered lactoferrin restores humoral immune response in inummocompromised mice. Immunol. Lett., 2003, 89, 9-15.
167. Togawa, J.; Nagase, H.; Tanaka, K.; Inamori, M.; Nakajima, A.; Ueno, N.; Saito, T.; Sekihara, H. Oral administration of lactofenin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J. Gastroenterol. Hepatol., 2002, 17, 1291-1298.
168. Zimecki, M.; Dawiskiba, J.; Zawitska, B.; Krawczyk, Z.; Kruzel, M. Bovine lactoferrin decreases histopathological changes in the liver and regulates cytokine production by splenocytes of obstructive jaundiced rats. Inflamm. Res., 2003, 52, 305-310.
169. Hayashida, K.; Takeuchi, T.; Harada, E. Lactoferrin enhances peripheral opioid-mediated antinociception via nitric oxide in rats. Eur. J. Pharmacol., 2004, 484, 175-181.
170. Kanwar, J.R.; Krissansen, G.W. 2006, WO/2008/079030 Application No.: PCT/NZ2007/000389, 2006-05-26.
171. Kamemori, N.; Takeuchi, T.; Hayashida, K.; Harada, E. Suppressive effects of milk-derived lactoferrin on psychological stress in adult rats. Brain Res., 2004, 1029, 34-40.
172. Cornish, J.; Callon, K. E.; Naot, D.; Palmano, K. P.; Banovic, T.; Bava, U.; Watson, M.; Lin, J. M.; Tong, P. C.; Chen, O., Chan, V. A.; Reid, H. E.; Fazzalari, N.; Baker, H. M.; Baker, E. N.; Haggarty, N. W.; Grey, A. B.; Reid, I. R. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology, 2004, 145, 4366-4374.
173. Kruzel, M. L.; Harari, Y.; Chen, C. Y.; Castro, G. A. Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation, 2000, 24, 33-44.
174. Kruzel, M. L.; Harari, Y.; Mailman, D.; Actor, J. K.; Zimecki, M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin. Exp. Immunol., 130, 25-31.
175. Kruzel, M. L.; Zimecki, M. Lactoferrin and immunologic dissonance: clinical implications. Arch. Immunol. Ther. Exp., 2002, 50, 325-333.
176. Kruzel, M. L. Immunomodulation by nutrition: immunomodulation by nutrition: A new challenge for milk-derived proteins and peptides. Anti-Aging Med. Ther., 2003, 5, 347-355.
177. Kruzel, M. L.; Bacsi, A.; Ghoudhury, B.; Sur, S.; Boldogh, I. Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma. Immunology, 2006, 119, 159-166.
178. Machnicki, M.; Zimecki, M.; Zagulski, T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int. J. Exp. Pathol., 1993, 74, 433-439.
179. Zimecki, M.; Kruzel, M. Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice. Immunol. Lett., 2000, 74, 183-8.
180. Sasaki, Y.; Otsuki, K.; Hasegawa, A.; Sawada, M.; Ghiba, H.; Negishi, M.; Nagatsuka, M.; Okai, T. Preventive effect of recombinant human lactoferrin on lipopolysaccharide-induced preterm delivery in mice. Acta Obstet. Gynecol. Scand., 2004, 83, 1035-1038.
181. Appelmelk, B. J.; An, Y. Q.; Geerts, M.; Thijs, B. G.; de Boer, H. A.; MacLaren, D. M.; de Graaff, J.; Nuijens, J. H. Lactoferrin is a lipid A-binding protein. Infect. Immun., 1994, 62, 2628-2632.
182. Elass-Rochard, E.; Legrand, D.; Salmon, V.; Roseanu, A.; Trif, M.; Tobias, P. S.; Mazurier, J.; Spik, G. Lactoferrin inhibits the endotoxin interaction with CD 14 by competition with the lipopoly saccharidebinding protein. Infect. Immun., 1998, 66, 486-491.
183. Hayes, T. G.; Falchook, G. F.; Varadhachary, G. R.; Smith, D. P.; Davis, L. D.; Dhingra, H. M.; Hayes, B. P.; Varadhachary, A. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest. New Drugs, 2006, 24, 233-40.
184. Artym, J.; Zimecki, M.; Kuryszko, J.; Kruzel, M. L. Lactoferrin accelerates reconstitution of the humoral and cellular immune response during chemotherapy-induced immunosuppression and bone marrow transplant in mice. Stem Cells Dev., 2005, 14, 548-55.
185. Okada, S.; Tanaka, K.; Sato, T.; Ueno, H.; Saito, S.; Okusaka, T.; Sato, K.; Yamamoto, S.; Kakizoe, T. Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn. J. Cancer Res., 2002, 93, 1063-1069.
186. Zimecki, M.; Spiegel, K.; Waszczyk, A.; Kohler, A.; Kruzel, M. L. Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells. Arch. Immunol. Ther. Exp., 1999, 47, 113-118.
187. Zimecki, M.; Waszczyk, A.; Wojciechowski, R.; Dawiskiba, J.; Kruzel, M. Lactoferrin regulates the immune responses in postsurgical patients. Arch. Immunol. Ther. Exp., 2001, 49, 325-333.
188. Frydecka, I.; Zimecki, M.; Bocko, D.; Kosmaczewska, A.; Teodorowska, R.; Ciszak, L.; Kruzel, M.; Wlodarska-Polinska, J.; Kuliczkowski, K.; Kornafel, J. Lactoferrin-induced up-regulation of zeta chain expression in peripheral blood T lymphocytes from cervical cancer patients. Anticancer Res., 2002, 22, 1897-1901.
189. DiMario, F.; Aragona, G.; Bo, N. D.; Ingegnoli, A.; Cavestro, G. M.; Moussa, A. M.; Iori, V.; Leandro, G.; Pilotto, A.; Franze, A. Use of lactoferrin for Helicobacter pylori eradication. preliminary results. J. Can. Gastroenterol., 2003, 36, 396-398.
190. Inoue, M.; Okamura, T.; Yasui, M.; Sakata, N.; Yagi, K.; Kawa, K. Lactoferrin for gut GVHD. Bone Marrow Transplant, 2001, 28, 1091-1092.
191. Janusz, M.; Staroscik, K.; Zimecki, M.; Wieczorek, Z.; Lisowski, J. Chemical and physical characterization of a proline-rich polypeptide from sheep colostrum. Biochem. J., 1981, 199, 9-15.
192. Kruzel, M. L.; Janusz, M.; Lisowski, J.; Fischleigh, R. V.; Georgiades, J. A. Towards an understanding of biological role of colostrinin pepudes. J. Mol. Neurosci., 2001, 17, 379-389.
193. Wieczorek, Z.; Zimecki, M.; Janusz, M.; Staroscik, K.; Lisowski, J. Proline-rich polypeptide from ovine colostrum: its effect on skin permeability and on the immune response. Immunology, 1979, 36, 875-881.
194. Zimecki, M.; Janusz, M.; Starocik, K.; Lisowski, J.; Wieczorek, Z. Effect of prohne-rich polypeptide on donor cells in graftversus-host reaction. Immunology, 1982, 47, 141-7.
195. Staroscik, K.; Janusz, M.; Zimecki, M.; Wieczorek, Z.; Lisowski, J. Immunologically active nonapeptide fragment of a proline-rich polypeptide from ovine colostrum: amino acid sequence and immunoregulatory properties. Mol. Immunol., 1993, 20, 1277-1282.
196. Zimecki, M.; Pierce, C. W.; Janusz, M.; Wieczorek, Z.; Lisowski, J. Proliferative response of T lymphocytes to a proline-rich polypeptide (PRP): PRP mimics mitogenic activity of II-1. Arch. Immunol. Ther. Exp., 1987, 35, 339-349.
197. Wieczorek, Z.; Zimecki, M.; Spiegel, K.; Lisowski, J.; Janusz, M. Differentiation of T cells into helper cells from immature precursors: identification of a target cell for a prohne-rich polypeptide (PRP). Arch. Immunol. Ther. Exp., 1989, 37, 313-322.
198. Zablocka, A.; Janusz, M.; Rybka, K.; Wirkus-Romanowska, I.; Kupryszewski, G.; Lisowski, J. Cytokine-inducing activity of a proline-rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs. Eur. Cytokine, 2001, 12, 462-467.
199. Hraba, T.; Wieczorek, Z.; Janusz, M.; Lisowski, J.; Zimecki, M. Effect of proline-rich polypeptide on experimental autoinumme response to erythrocytes. Arch. Immunol. Ther. Exp., 1986, 34, 437-443.
200. Zimecki, M.; Hraba, T.; Janusz, M.; Lisowski, J.; Wieczorek, Z. Effect of a proline-rich polypeptide (PRP) on the development of hemolytic anemia and survival of New Zealand black (NZB) mice. Arch. Immunol. Ther. Exp., 1991, 39, 461-467.
201. Boldogh, I.; Liebenthal, D.; Hughes, T. K.; Juelich, T. L.; Georgiades, J. A.; Kruzel, M. L.; Stanton, G. J. Modulation of 4HNE-mediated signaling by proline-rich polypeptides from ovine colostrum. J. Mol. Neurosci., 2003, 20, 125-134.
202. Schuster, D.; Rajendran, A.; Hui, S. W.; Nicotera, T.; Srikrishnan, T.; Kruzel, M. L. Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid. Neuropeptides, 2005, 39, 419-26.
203. Bacsi, A.; Stanton, J.; Hughes, T.; Kruzel, M.; Boldogh, I. Colostrinin-driven neurite outgrowth requires p53 activation in PC 12 cells. Cell Mol. Neurobiol., 2005, 25, 1123-1139.
204. Stewart, M. G.; Banks, D. Enhancement of long-term memory retention by Colostrinin in one-day-old chicks trained on a weak passive avoidance learning paradigm. Neuroblol. Learn Mem., 2006, 86, 66-71.
205. Bacsi, A.; Woodberry, M.; Kruzel, M.; Boldogh, I. Colostrinin attenuates mitochondrial dysfunction and decreases generation of reactive oxygen species. Neuropeptides, 2007, 41, 93-101.
206. Leszek, J.; Inglot, A. D.; Janusz, M.; Byczkiewicz, F.; Kiejna, A.; Georgiades, J.; Lisowski, J. Colostrinin proline-rich polypeptide complex from ovinc colostrum - a long-term study of its efficacy in Alzheimer's disease. Med. Sci. Monit., 2002, 8, 193-6.
207. Leszek, J.; Inglot, A. D.; Janusz, M.; Lisowski, J.; Krukowska, K.; Georgiades, J. A. Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease: a double-blind, placebo-controlled study. Arch. Immunol. Ther. Exp., 1999, 47, 377-385.
208. Bilikiewicz, A.; Gaus, W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J. Alzheimer's Dis., 2004, 6, 17-26.
209. Lahov, E.; Regelson, W. Antibacterial and inummostiniulating casein-derived substances from milk: casecidin, isracidin pepudes. Food Chem. Toxicol., 1996, 34, 131-145.
210. Reynolds, E. C. The prevention of sub-surface demineralization of bovine enamel and change in plaque composition by casein inan intra-oral model. Dent. Res., 1987, 66, 1120-7.
211. Hay, K. D.; Thomson, W. M. A clinical trial of the anticaries efficacy of casein derivatives complexed with calcium phosphate in patients with salivary gland dysfunction. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2002, 93, 210-215.
212. Tsuchita, H.; Goto, T.; Shimizu, T.; Vonehara, Y.; Kuwata, T. Dietary casein phosphopeptides prevent bone loss in aged ovariec-tomized raxa. J. Nutr., 1996, 126, 86-93.
213. Noursadeghi, M.; Bickerstaff, M. C.; Herbert, J.; Moyes, D.; Cohen, J.; Pepys, M. B. Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection. J. Immunol., 2002, 169, 913-919.
214. Otani, H.; Nakano, K.; Kawahara, T. Stimulatory effect of a dietary casein phosphopeptide preparation on the mucosal IgA response of mice to orally ingested lipopolysaccharide from Salmonella typhimurium. Biosci. Biotechnol. Biochem., 2003, 67, 729-735.
215. Hermitte, L.; Atlan-Gepner, C.; Payan, M. J.; Mehelleb, M.; Vialettes, B. Dietary protection against diabetes in NOD mice: lack of a major change in the immune system. Diabetes Metab., 1995, 21, 261-268.
216. Wang, G.S.; Gruber, H.; Smyth, P.; Pulido, O.; Rosenberg, L.; Duguid, W.; Scott, F. W. Hydrolysed casein diet protects BB rats from developing diabetes by promoting islet neogenesis. J Autoimmunol., 2000, 15, 407-416.
217. McIntosh, G. H.; Regester, G. O.; LeLeu, R. K.; Royle, P. J.; Smithers, G. W. Dairy proteins protect against dimediylhydmzine-induced intestinal cancers in TMH. J. Nutr., 1995, 125, 809-816.
218. Nakajima, M.; Shinoda, I.; Samejima, Y.; Miyauchi, H.; Fukuwatari, Y.; Hayasawa, H. Kappa-casein suppresses melanogenesis in cultured pigment cells. Pigment. Cell Res, 1996, 9, 235-239.
219. Gun, Z.; Narbaitz, R.; Fryer, J. N. Effects of excess iodine in chick embryo thyroid follicles: initial inhibition and subsequent hypertrophy. J. Anat., 1991, 176, 157-67.
220. Robert, M. C.; Razanarne, A.; Mutter, M.; Juillerat, M. A. Identification of angiotensin-1-converting enzyme inhibitory peptides derived from sodium caseinate hydrolysates produced by Lactobacillus helveticus NCC 2165. J. Agric. Food Chem., 2004, 52, 6923-6931.
221. Jakobsson, I.; Lothe, L.; Ley, D.; Borschel, M. W. Effectiveness of casein hydrolysate feedings in infants with colic. Acta Paediatr., 2000, 89, 18-21.
222. Brody, E. P. Biological activities of bovine glycomacropeptide. Br. J. Nutr., 2000, 84 (Suppl 1): S39-46.
223. Silva-Hernandez, E. R.; Nakano, T.; Ozimek, L. Isolation and analysis of kappa-casein glycomacropeptide from goat sweet whey. J. Agric. Food Chem., 2002, 50, 2034-2038.
224. Li, E. W.; Mine, Y. Immunoenhancing effects of bovine glycomacropeptide and its derivatives on the proliferative response and phagocytic activities of human macrophagelike cells, U937. J. Agric. Food Chem., 2004, 52, 2704-2708.
225. Kawasaki, Y.; Isoda, H.; Tanimoto, M.; Dosako, S.; Idota, T.; Ahiko, K. Inhibition by lactoferrin, and kappa-casein glycomacropeptide of binding of Cholera toxin to its receptor. Biosci. Biotechnol. Biochem., 1992, 56, 195-8.
226. Neeser, J. R.; Chambaz, A.; DelVedovo, S.; Prigent, M. J.; Guggenheim, B. Specific and nonspecific inhibition of adhesion of oral actinomyces and streptococci to erythrocytes and polystyrene by caseinoglycopeptide derivatives. Infect. Immun., 1998, 56, 3201-3208.
227. Balditsollier, C.; Droner, L.; Pignaud, G.; Chevallier, C.; Caen, J.; Fiat, A. M.; Izquierdo, C.; Jolles, P. Effect of kappa-casein split peptides on platelet aggregation and on thrombus formation in the guinea-pig. Thromb. Res., 1996, 81, 427-437.
228. Bruck, W. M.; Kelleher, S. L.; Gibson, G. R.; Nielsen, K. E.; Chatterton, D. E.; Lonnerdal, B. rRNA probes used to quantify the effects of glycomacropeptide and alpha-lactalbumin supplementation on the predominant groups of intestinal bacteria of infant rhesus monkeys challenged with enteropathogenic Escherichia coli. J. Pediatr. Gasiroenterol. Nutr., 2003, 37, 273-280.
229. Kelleher, S.L.; Chatterton, D.; Nielsen, K.; Lonnerdal, B. Glycomacropeptide and alpha-lactalbumin supplementation of infant formula affects growth and nutritional status in infant rhesus monkeys. Am. J. Clin. Nutr., 2003, 11, 1261-1268.
230. Ozsan, H..G.; Pehlivan, M.; Demirkati, F.; Undar, B.; Sayan, M.; Cehreli, C. High lactoferrin levels in disseminated intravascular coagulation and its possible negative role in coagulation. Thromb. Res., 2000, 98(1), 111-4.
231. Mizuno, S.; Matsuura, K.; Gotou, T.; Nishimura, S.; Kajimoto, O.; Yabune, M.; Kajimoto, Y.; Yamamoto, N. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br. J. Nutr., 2005, 94, 84-91.
232. Townsend, R. R.; McFadden, C. B.; Ford, V.; Cadee, J.A. A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (CI2 peptide) in human essential. Am. J. Hypertens., 2004, 17, 1056-8.
233. Qasba, P. K.; Kumar, S. Molecular divergence of lysozymes and alpha-lactalbumin. Crit. Rev. Biochem. Mol. Biol., 1997, 32, 255-306.
234. Ng, T. B.; Lam, T. L.; Au, T. K.; Ye, X. Y.; Wan, C. C. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, protease and integrase by bovine milk proteins. Life Sci., 2001, 69, 2217-2223.
235. Matsumoto, H.; Shimokawa, Y.; Ushida, Y.; Toida, T.; Hayasawa, H. New biological function of bovine alpha-lactalbumin: protective effect against ethanol- and stress-induced gastric mucosal injury in rats. Biosci. Biotechnol. Biochem., 2001, 65, 1104-1111.
236. Ushida, Y.; Shimokawa, Y.; Matsumoto, H.; Toida, T.; Hayasawa, H. Effects of bovine alpha-lactalbumin on gastric defense mechanisms in naive rats. Biosci. Biotechnol. Biochem., 2003, 67, 577-583.
237. Markus, C. R.; Olivier, B.; Panhuysen, G. E.; VanDer Gugten, J.; Alles, M. S.; Tuiten, A.; Westenberg, H. G.; Fekkes, D.; Koppeschaar, H. F.; de Haan, E. E. The bovine protein alpha-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids, and in vulnerable subjects raises brain serotonin activity, reduces cortisol concentration, and improves mood under stress. Am. J. Clin. Nutr., 2000, 71, 1536-1544.
238. Nurminen, M. L.; Sipola, M.; Kaarto, H.; Pihlanto-Leppala, A.; Piilola, K.; Korpela, R.; Tossavainen, O.; Korhonen, H.; Vapaatalo, H. Alpha-lactorphin lowers blood pressure measured by radio-telemetry in normotensive and spontaneously hypertensive rats. Life Sci., 2000, 66, 1535-1543.
239. Sipola, M.; Finckenberg, P.; Vapaatalo, H.; Pihlanto-Leppala, A.; Korhonen, H.; Korpela, R.; Nurminen, M. L. Alpha-lactorphin and beta-lactorphin improve arterial function in spontaneously hypertensive rats. Life Sci., 2002, 71, 1245-1253.
240. Maes, W.; Van Camp, J.; Vermeirssen, V.; Hemeryck, M.; Ketelslegers, J. M.; Schrezenmeir, J.; Van Oostveldt, P.; Huyghebaert, AInfluence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelian-1 by endothelial cells. Regul. Pept., 2004, 118, 105-109.
241. Murakami, M.; Tonouchi, H.; Takabashi, R.; Kitazawa, H.; Kawai, Y.; Negishi, H.; Saito, T. Structural analysis of a new antihypertensive peptide (beta-lactosin B) isolated from a commercial whey product. J. Dairy Sci., 2004, 87, 1967-1974.
242. Lv, G. S.; Hou, G. C.; Fu, X. Y. Expression of milk-derived anti-hypertensive peptide in Escherichia coli. J. Dairy Sci., 2003, 86, 1927-1931.
243. Eichenberger, J. R.; Hadom, B.; Schmidt, B. J. A semi-elemental diet with low osmolarity and high content of hydrolyzed lactalbumin in the treatment of acute diarrhea in malnourished children. Arq. Gastroenterol., 1984, 21, 130-5.
244. Sack, R. B.; Castrellon, J.; Delia Sera, E.; Goepp, J.; Burns, B.; Croll, J.; Tseng, P.; Reid, R.; Carrizo, H.; Santosham, M. Hydrolyzed lactalbumin-based oral rehydration solution for acute diarrhea in infants. Acta Paediatr., 1994, 83, 819-824.
245. Fischer, W.; Gustafsson, L.; Mossberg, A. K.; Gronli, J.; Mork, S.; Bjerkvig, R.; Svanborg, C. Human alpha-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Res., 2004, 64, 2105-2112.
246. Gustafsson, L.; Leijonhufvud, I.; Aronsson, A.; Mossberg, A. K.; Svanborg, C. Treatment of skin papillomas with topical alphalactalbumin-oleic acid. N. Engl. J. Med., 2004, 350, 2663-2672.
247. Proctor, V. A.; Cunningham, F. E. The chemistry of lysozyme and its use as a food preservative and a pharmaceutical. Crit. Rev. Food Sci. Nutr., 1988, 26, 359-395.
248. Bol'shakova, A. M.; Shcherbakova, E. G.; Ivanova, S. D.; Medvedeva, M. M.; Zhuravleva, T. P. Lysozyme in the feeding of premature infants with mixed pathology. Antibiotiki, 1984, 29, 784-790.
249. Edde, L.; Hipolito, R. B.; Hwang, F. F.; Headon, D. R.; Shalwitz, R. A.; Sherman, M. P. Lactoferrin protects neonatal rats from gutrelated systemic infection. Am. J. Physiol. Gastrointest. Liver, 2001, 1, G1 140-G1 150.
250. Ogundele, M. O. A novel anti-inflammatory activity of lysozyme: modulation of serum 3. Bianchi C, Is Fleming's lysozyme an analgesic agent? An experimental reappraisal of clinical data. Mediators Inflamm., 1998, 7, 363-5.
251. van Hooijdonk, A. C.; Kussendrager, K. D.; Steijns, J. M. in vivo antimicrobial and antiviral activity of components in bovine milk and colostrum involved in non-specific defence. Br. J. Nutr., 2000, 84, SI27-SI34.
252. Martinez-Gomis, J.; Fernandez-Solanas, A.; Vinas, M.; Gonzalez, P.; Planas, M. E.; Sanchez, S. Effects of topical application of free and liposome-encapsulated lactoferrin and lactoperoxidase on oral microbiota and dental caries in rats. Arch. Oral Biol., 1999, 44, 901-906.
253. Wray, C.; McLaren, I. A note on the effect of the lactoperoxidase systems on salmonellas in vitro and in vivo. J. Appl. Bacteriol., 1987, 62, 115-118.
254. Still, J.; Delahaut P.; Coppe, P.; Kaeckenbeeck, A.; Perraudin, J. P. Treatment of induced enterotoxigenic colibacillosis (scours) in calves by the lactoperoxidase system and lactoferrin. Ann. Rech. Vet., 1990, 21, 143-152.
255. Nagendra, P. S. Effects of milk-derived bioactives: an overview. J. Nutr., 2000, 84, S3-S10.
256. Brantl, V.; Teschemacher, H.; Henschen, A.; Lottspeich, F. Novel opioid peptides derived from casein (β-casomorphins). Physiol. Chem., 1979, 360, 1211-1216.
257. Henschen, A.; Lottspeich, F.; Brand, V.; Teschemacher, H. Novel opioid peptides derived from casein, β-casomorphins. II: structure of active components from bovine casein peptone. Hoppe-Seyler's Physiol. Chem., 1979, 360, 1217-1224.
258. Kelley, C. P.; Chetman, S.; Keates, S.; Bostwick, E. F.; Roush, A. M.; Castagliuolo, I.; Lamont, J. T.; Pothoulakis, C. Survival of anti-Clostridium difficile bovine immunoglobuhn concentrate in the human gastrointestinal tract. Antimicrob. Agents Chemother., 1997, 41, 236-241.
259. Holt, C.; Horne, D. S. The hairy casein micelle: evolution of the concept and its implications for dairy technology. Neth. Milk Dairy J., 1996, 50, 85 -112.
260. Scholz-Ahrens, K. E.; Schrezenmeir, J. Effects of bioactive substances in milk on mineral and trace element metabolism with special reference to casein phosphopeptides. Br. J. Nutr., 2000, 84, S147-S153.
261. Heany, R. P.; Saito, Y.; Orimo, H. Effect of casein phosphopeptide on absorbability of co-ingested calcium in normal postmenopausal women. J Bone Miner. Metab., 1994, 12, 77-81.
262. Hansen M.; Sandström, B.; Lönnerdal, B. Effect of casein phosphopeptide on absorbability of co-ingested calcium in normal postmenopausal women. Pediair. Res., 1996, 40, 547-552.
263. Hansen, M.; Sandström, B.; Jensen, M.; Sörensen, S. S. Casein phosphopeptides improve zinc and calcium absorption from rice-based but not from whole-grain infant cereal. J. Pediatr. Gastrointest. Nutr., 1997, 24, 56-62.
264. Yuan, Y. V.; Kitts, D. D. Confirmation of calcium absorption and femoral utilization in spontaneously hypertensive rats fed casein phosphopeptide diets. Nutr. Res., 1991, 11, 1257-1272.
265. Aimutis, W. R. Bioactive properties of milk proteins with particular focus on anticariogenesis. J. Nutr., 2004, 134, 989S-995S.
266. Grenby, T. H.; Andrews, A. T.; Mistry, M.; Williams, R. J. H. Dental caries-protective agents in milk products: Investigations in vitro. J. Dent., 2001, 29, 83-92.
267. Scholz-Ahrens, K. E.; Schrezenmeir, J. Effects of bioactive substances in milk on mineral and trace element metabolism with special reference to casein phosphopeptides. Br. J. Nutr., 2000, 84, S147-S153.